These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 36476351)

  • 81. LncRNA MEG3 enhances cisplatin sensitivity in non-small cell lung cancer by regulating miR-21-5p/SOX7 axis.
    Wang P; Chen D; Ma H; Li Y
    Onco Targets Ther; 2017; 10():5137-5149. PubMed ID: 29123412
    [TBL] [Abstract][Full Text] [Related]  

  • 82. CircPTK2 inhibits cell cisplatin (CDDP) resistance by targeting miR-942/TRIM16 axis in non-small cell lung cancer (NSCLC).
    Wang Y; Wu Y; Xie S
    Bioengineered; 2022 Feb; 13(2):3651-3664. PubMed ID: 35230201
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Circ_0030411 aggravates cisplatin-resistance in non-small cell lung cancer by serving as a miR-495-3p sponge to enhance CCND1 expression.
    Zhang J; Cui X; Qu H; Zhang Y
    J Chemother; 2023 Oct; 35(6):550-562. PubMed ID: 36591727
    [TBL] [Abstract][Full Text] [Related]  

  • 84. p32/OPA1 axis-mediated mitochondrial dynamics contributes to cisplatin resistance in non-small cell lung cancer.
    Yu CX; Peng ZQ; Wang T; Qu XH; Yang P; Huang SR; Jiang LP; Tou FF; Han XJ
    Acta Biochim Biophys Sin (Shanghai); 2024 Jan; 56(1):34-43. PubMed ID: 38151998
    [TBL] [Abstract][Full Text] [Related]  

  • 85. CircRNA_100565 contributes to cisplatin resistance of NSCLC cells by regulating proliferation, apoptosis and autophagy via miR-337-3p/ADAM28 axis.
    Zhong Y; Lin H; Li Q; Liu C; Shen J
    Cancer Biomark; 2021; 30(2):261-273. PubMed ID: 33682697
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Long-non-coding RNA AK001058: A genetic biomarker in cisplatin sensitivity of non-small-cell lung carcinoma.
    Deng Y; Li H; Liu C; Xia X; Lv Y; Zhang D; Liang J
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):217-220. PubMed ID: 38279432
    [TBL] [Abstract][Full Text] [Related]  

  • 87. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
    Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
    Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
    [TBL] [Abstract][Full Text] [Related]  

  • 88. β-elemene enhances cisplatin sensitivity of non-small cell lung cancer cells via the miR-17-5p/STAT3 axis.
    Qian T; Wenxian T; Anbing H
    Chem Biol Drug Des; 2024 Jan; 103(1):e14395. PubMed ID: 37973414
    [TBL] [Abstract][Full Text] [Related]  

  • 89. MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
    Lu M; Hu C; Wu F; Shu L; Pan Y; Liu X; Liu P; Ma F; Deng C; Huang M
    Lung Cancer; 2020 Sep; 147():193-197. PubMed ID: 32731058
    [TBL] [Abstract][Full Text] [Related]  

  • 90. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer.
    Tian R; Zhang C; Xiong F; Chen H
    Front Biosci (Landmark Ed); 2020 Mar; 25(5):948-960. PubMed ID: 32114419
    [TBL] [Abstract][Full Text] [Related]  

  • 91. CircAKT3 inhibits glycolysis balance in lung cancer cells by regulating miR-516b-5p/STAT3 to inhibit cisplatin sensitivity.
    Xu Y; Jiang T; Wu C; Zhang Y
    Biotechnol Lett; 2020 Jul; 42(7):1123-1135. PubMed ID: 32170433
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells.
    Yu G; Zhong N; Chen G; Huang B; Wu S
    Tumour Biol; 2014 Oct; 35(10):10341-9. PubMed ID: 25038915
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Circular RNA-AnnexinA7 accelerates cisplatin resistance in non-small cell lung cancer via modulating microRNA-545-3p to mediate Cyclin D1.
    Yao J; Zhang HY; Gu S; Zou JL; Zhang Q; Qu RC
    Acta Biochim Pol; 2023 May; 70(2):295-304. PubMed ID: 37220402
    [TBL] [Abstract][Full Text] [Related]  

  • 94. miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer.
    Yu C; Li B; Wang J; Zhang Z; Li S; Lei S; Wang Q
    Ann Clin Lab Sci; 2021 Sep; 51(5):625-637. PubMed ID: 34686504
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
    Li W; Liu X; Zhang G; Zhang L
    Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
    [TBL] [Abstract][Full Text] [Related]  

  • 96. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Knockdown of miR-15b partially reverses the cisplatin resistance of NSCLC through the GSK-3β/MCL-1 pathway.
    Lu T; Lu W; Jia C; Lou S; Zhang Y
    Adv Clin Exp Med; 2021 Aug; 30(8):849-857. PubMed ID: 34286518
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Long noncoding LUCAT1 promotes cisplatin resistance of non-small cell lung cancer by promoting IGF-2.
    Wang W; Dong ML; Zhang W; Liu T
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5229-5234. PubMed ID: 31298373
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
    Wu Y; Guo L; Liu J; Liu R; Liu M; Chen J
    Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):1-7. PubMed ID: 24398307
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Depletion of circPDSS1 inhibits ITGA11 production to confer cisplatin sensitivity through miR-515-5p in gastric cancer.
    Wang Y; Tang S; Li L; Sun C; Liu Y; Zhao Y
    J Chemother; 2023 Oct; 35(6):514-526. PubMed ID: 36484486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.